Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
Fiche publication
Date publication
mars 2018
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L
Lien Pubmed
Résumé
Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated.
Mots clés
Adult, Child, Clinical Trials as Topic, psychology, Data Interpretation, Statistical, Female, Humans, Inflammatory Bowel Diseases, therapy, International Agencies, Male, Perception, Physicians, psychology, Practice Patterns, Physicians', statistics & numerical data, Remission Induction, Societies, Medical, Surveys and Questionnaires
Référence
Aliment. Pharmacol. Ther.. 2018 Mar;47(6):773-783